By targeting the inflammatory pathways linked to high eosinophil levels, Dupixent offers a new avenue for controlling symptoms and reducing exacerbations, potentially improving the quality of life ...

It is the first biologic drug licensed for use in adolescents, and unlike topical treatments it targets an underlying pathway that drives the disease. In England, Dupixent was originally ...

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

This makes the new indication for Dupixent very important for Sanofi as it searches for a blockbuster to transform its fortunes. The FDA is set to make a decision on Dupixent’s new indication on ...

Dupixent (dupilumab ... Other biologics under development have been designed to target these immune pathways or similar immune pathways. For example, lebrikizumab is also designed to target ...

An oral STAT6 degrader has the potential to be a category-defining medicine for T helper type 2 (Th2) inflammatory disorders, and could become an “oral Dupixent,” Khurshid said. “We see ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Dupixent ® is now used to treat over a million ... presenting an unmet need for more specific inhibition of the intrinsic coagulation pathway. Multiple approaches to obesity: Regeneron is ...